Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Cenicriviroc Mesylate

Catalog No: tcsc0032631

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Specifications

CAS No:
497223-28-6

Formula:
$C_{42}H_{56}N_4O_7S_2$

Pathway:
Immunology/Inflammation;GPCR/G Protein;Anti-infection

Target:
CCR;CCR;HIV

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 107.5 mg/mL (135.55 mM)

Alternative Names:
TAK-652 Mesylate;TBR-652 Mesylate

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
793.05

Product Description

Cenicriviroc is a dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

IC50 & Target: CCR2/CCR5[1]

In Vitro: Migration of mouse monocytes in response to carbon tetrachloride (CCL2) is reduced following pre-treatment with Cenicriviroc Mesylate (CVC) at a concentration of 1 μM. Compare to untreated and unstimulated cells, the average fold change in migrating cells (±SD) is 0.8±0.2 (p>0.05) and 0.7±0.4 (p>0.05) for CCL2-stimulated cells treated with Cenicriviroc Mesylate and unstimulated cells treated with Cenicriviroc Mesylate, respectively[1]. Phenotypic susceptibility testing shows, for the four R5-tropic HIV-2 isolates, a median EC_{50} for Cenicriviroc Mesylate of 0.39 nM (0.03, 0.33, 0.45 and 0.98 nM). The dual-tropic and the X4-tropic HIV-2 strains are resistant to Cenicriviroc Mesylate with EC_{50} at >1000 nM, and Maximum percentages of inhibition (MPI) at 33% and 4%, respectively[2].

In Vivo: Cenicriviroc Mesylate (CVC) treatment leads to dose-related decrease in monocyte/macrophage recruitment, of similar or greater magnitude than those observed with dexamethasone (positive control), and achieving statistical significance at doses ≥20 mg/kg/day (p[1].